Company: RGNT
Filing Date: 2025-01-27
Form Type: DRS/A
Source: 0001213900-25-006676
Chunk: 296

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-27
Form: DRS/A
Chunk 296
---
and shall bear interest at 8% per annum until maturity commencing as of September 1, 2024. In addition, at Maturity Date, the Company
shall pay the Lenders an aggregate risk premium equal to $50 (risk premium). Furthermore, upon the occurrence of an IPO, the 2024 Loan
Agreements lenders shall be granted warrants to purchase such number of ordinary shares equal to two times the loan amount, based on a
price per share equal to 75% of the lowest price per share of the Company’ ordinary shares during the first 5 trading days as of
such IPO consummation.

In April 2024, the Company received an
approval from the EASME for its expenses as part of the Horizon 2020 Research and Innovation Framework Programme (refer to Note 9(4)).
As part of the approval, the Company received EURO 328 thousand which represents the remaining funds to be received by the Company for
this project.

In April 2024, the Company repaid the
outstanding loan balance from August 2023 loan which amounted to $325 (refer to Note 5).

In October 2024, the Company signed an
addendum to the 2020 CLA agreement (the “October 2024 Addendum”) pursuant to which certain lenders (the “Participating
Lenders”) under the 2020 CLAs will increase their CLA and up to an additional aggregate amount of $450, so that the 2020 CLAs of
the non-Participating Lenders shall bear interest at 8% per annum until maturity commencing as of July 1, 2024, and of the Participating
Lenders commencing as of March 31, 2025. In addition, pursuant the October 2024 Addendum, upon the earlier of March 31, 2025 or occurrence
of an IPO, the CLA 2020 principal and accrued interest will be automatically converted into 243,955 ordinary shares based on a pre money
valuation of $5,150. In addition, the Company will pay to the Participating Lender an amount of $340 as a risk premium, which will be
automatically converted in the same terms as above into 221,456 Ordinary Shares of the Company. As of November 20, 2024, the Company received
$337.5 out of the $450 proceeds.

Between October 2024 and November 2024, the